Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate.

Miller PD, Shergy WJ, Body JJ, Chen P, Rohe ME, Krege JH

The Journal of rheumatology1 Aug 2005Cited by 23 (Europe PMC)

PMID16078334PepBankPUB-16078334

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

01HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide reduced any back pain risk versus alendronate during the trial.
In plain wordsIn women with osteoporosis, teriparatide reduced back pain risk versus alendronate during treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseAny back pain during trial
Study
n = 146
Comparator
Alendronate 10 mg daily
Outcome group
Pain · Musculoskeletal
Studied dose
40 microg daily · injection · median 14 monthsAs given in this study (human).
Measurements
Relative risk
0.27 ratio
any back pain versus alendronate
Source sentences
Summary
During the comparator trial, compared with women randomized to alendronate 10 mg, women randomized to teriparatide 40 microg had reduced risk for any back pain (relative risk 0.27, 95% CI 0.09-0.82) and moderate or severe back pain (relative risk 0.19, 95% CI 0.04-0.86).
2 context sentences(design, population, supporting numbers)
Summary · context
In the comparator trial, women were randomized to receive either daily self-injected teriparatide 40 microg plus an oral placebo (n = 73), or daily oral alendronate 10 mg plus self-injected placebo (n = 73).
Summary · context
Treatment was for a median 14 months.
Report a problemFND-1607833401
02HumanRandomized controlled trialEfficacy outcome
In women with osteoporosis, teriparatide reduced moderate or severe back pain risk versus alendronate during the trial.
In plain wordsIn women with osteoporosis, teriparatide reduced moderate or severe back pain versus alendronate during treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseModerate or severe back pain during trial
Study
n = 146
Comparator
Alendronate 10 mg daily
Outcome group
Pain · Musculoskeletal
Studied dose
40 microg daily · injection · median 14 monthsAs given in this study (human).
Measurements
Relative risk
0.19 ratio
moderate or severe back pain versus alendronate
Source sentences
Summary
During the comparator trial, compared with women randomized to alendronate 10 mg, women randomized to teriparatide 40 microg had reduced risk for any back pain (relative risk 0.27, 95% CI 0.09-0.82) and moderate or severe back pain (relative risk 0.19, 95% CI 0.04-0.86).
2 context sentences(design, population, supporting numbers)
Summary · context
In the comparator trial, women were randomized to receive either daily self-injected teriparatide 40 microg plus an oral placebo (n = 73), or daily oral alendronate 10 mg plus self-injected placebo (n = 73).
Summary · context
Treatment was for a median 14 months.
Report a problemFND-1607833402
03HumanObservational studyEfficacy outcome
In women, the back pain difference favoring teriparatide versus alendronate persisted through the trial plus 18 additional months.
In plain wordsIn women, less back pain after teriparatide versus alendronate persisted through extended follow-up.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseBack pain through extended follow-up
Study
n: not reported in source
Comparator
Alendronate 10 mg daily
Outcome group
Pain · Musculoskeletal
Studied dose
40 microg daily · injection · median 14 monthsAs given in this study (human).
Source sentences
Summary
The differences in the reporting of back pain between the teriparatide treated women and the alendronate treated women were sustained during an interval including the comparator trial plus 18 additional months.
2 context sentences(design, population, supporting numbers)
Summary · context
In the comparator trial, women were randomized to receive either daily self-injected teriparatide 40 microg plus an oral placebo (n = 73), or daily oral alendronate 10 mg plus self-injected placebo (n = 73).
Summary · context
Treatment was for a median 14 months.
Report a problemFND-1607833403
04HumanObservational studyEfficacy outcome
In women, teriparatide recipients had numerically fewer back pain occurrences than alendronate recipients through the trial plus 30 additional months.
In plain wordsIn women, back pain was numerically less frequent after teriparatide than alendronate through later follow-up.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseAny back pain through later follow-up
Study
n: not reported in source
Comparator
Alendronate 10 mg daily
Outcome group
Pain · Musculoskeletal
Studied dose
40 microg daily · injection · median 14 monthsAs given in this study (human).
Source sentences
Summary
During an interval including the comparator trial plus 30 additional months, teriparatide treated patients had numerically fewer occurrences of back pain and moderate or severe back pain.
2 context sentences(design, population, supporting numbers)
Summary · context
In the comparator trial, women were randomized to receive either daily self-injected teriparatide 40 microg plus an oral placebo (n = 73), or daily oral alendronate 10 mg plus self-injected placebo (n = 73).
Summary · context
Treatment was for a median 14 months.
Report a problemFND-1607833404
05HumanObservational studyEfficacy outcome
In women, moderate or severe back pain was numerically less frequent after teriparatide than alendronate through the trial plus 30 additional months.
In plain wordsIn women, moderate or severe back pain was numerically less frequent after teriparatide than alendronate through later follow-up.
Peptide
Teriparatide (PTH 1-34)
Outcome
DecreaseModerate or severe back pain through later follow-up
Study
n: not reported in source
Comparator
Alendronate 10 mg daily
Outcome group
Pain · Musculoskeletal
Studied dose
40 microg daily · injection · median 14 monthsAs given in this study (human).
Source sentences
Summary
During an interval including the comparator trial plus 30 additional months, teriparatide treated patients had numerically fewer occurrences of back pain and moderate or severe back pain.
2 context sentences(design, population, supporting numbers)
Summary · context
In the comparator trial, women were randomized to receive either daily self-injected teriparatide 40 microg plus an oral placebo (n = 73), or daily oral alendronate 10 mg plus self-injected placebo (n = 73).
Summary · context
Treatment was for a median 14 months.
Report a problemFND-1607833405

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.